The reimbursement landscape is continuously evolving, with diverse requirements across key markets demanding coordinated, high-quality strategies. At IMAC, our team of specialists brings decades of expertise in health economics, real-world evidence generation, and market access strategies, with a strong focus on successful HTA submissions. With experience spanning over 28 countries and a wide range of therapeutic areas, our boutique approach allows us to integrate seamlessly with your team, delivering tailored support to achieve the best outcomes for your product.
IMAC’s team of HTA specialists brings unique expertise, with direct experience from both industry and reimbursement agencies across Europe, North America, and Australia. Our deep understanding of payer needs, paired with extensive skills in evidence generation and economic modeling, equips us to guide clients through even the most challenging HTA landscapes.
We excel in managing global HTA launches, adapting submissions to meet local market demands, and critiquing external HTA submissions to enhance messaging and overcome potential obstacles. IMAC provides end-to-end support for reimbursement submissions, ensuring each component aligns with a compelling value story for your therapy.
Our comprehensive HTA services include:
• Development of a robust Value Story: Integrated throughout the entire submission
• Targeted review of disease burden and natural history
• Systematic literature reviews (SLR): Covering clinical, utility, and economic data
• Network meta-analyses (NMA) and indirect treatment comparisons (ITC): To address evidence gaps
• Utility research and cost estimation
• Pre- and post-submission strategy: Ensuring a seamless path to positive
IMAC’s boutique approach means we integrate closely with your team, providing tailored strategic and technical support to secure the best outcomes for your therapy.
Successfully developed HTA submissions for a first-in-class, orphan oncology product in over 16 countries, including to NICE, SMC, and CDA (formerly CADTH).
Delivered market access strategy and HTA submissions for a major oncology project across 8 countries in the UK and Europe.
Fill out the form below, and our dedicated team will be in touch to discuss tailored solutions for you.